TIGIT in particular has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody vibostolimab ...

A Palm Beach Gardens man has teamed up with the Dana-Farber Foundation to raise funds for cancer research after losing his ...

The firm's next-generation sequencing-based test detects single nucleotide variants, insertions, and deletions in 22 genes.

Lung cancer screening with low-dose CT could have saved tens of thousands of lives—if only we'd listened to the data back in ...

Only half of study participants continued to get annual lung cancer screenings at least two years after their first.

Pembrolizumab plus concurrent chemoradiotherapy shows ongoing antitumor activity after about 5 years of follow-up in patients ...

An independent data monitoring board found that BeiGene’s ociperlimab was unlikely to significantly boost overall survival in patients with untreated NSCLC.

BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years after Novartis handed back the anti-TIGIT ...

The ultimate finish line, a world without cancer. Palm Beach Gardens man teams up with the Dana Farber Foundation to raise ...

ADRs came under pressure in the premarket on Thursday after the company announced its decision to halt a clinical program ...

BeiGene is ending development of its experimental lung-cancer treatment ociperlimab following the failure of a late-stage study. BeiGene on Thursday said it is stopping a Phase 3 trial of ociperlimab ...

Lung cancer screening has the potential to catch lung cancer early and save lives-but only if people get screened. Although lung cancer screening is recommended in the U.S. for certain individuals ...